Organization
Tang-Du Hospital
22 clinical trials
Clinical trial
A Randomized Control Trial of Baricitinib Administration in Patients With Moderate and Severe Traumatic Intracerebral Hemorrhage/ContusionsStatus: Not yet recruiting, Estimated PCD: 2025-07-01
Clinical trial
Efficacy and Safety of Furmonertinib for Epidermal Growth Factor Receptor (EGFR) Sensitive Mutation Positive Non-Small Cell Lung Cancer (NSCLC) Patients With Brain Metastasis: a Prospective Observational StudyStatus: Recruiting, Estimated PCD: 2024-09-30
Clinical trial
A Prospective, Randomized Controlled Clinical Study of The Efficacy and Safety of Taurine Combined With Sintilimab and Chemotherapy Versus Sintilimab Combined With Chemotherapy for Treatment of Advanced Gastric CancerStatus: Recruiting, Estimated PCD: 2025-07-31
Clinical trial
A Phase III, Open-label Extension Trial of tMG to Evaluate the Safety and Efficacy of Tocilizumab in Subjects With Generalized Myasthenia Gravis (gMG)Status: Recruiting, Estimated PCD: 2024-07-31
Clinical trial
A Prospective Single-center, Single-arm, Open-label Study of Sintilimab and Anlotinib Combined With Chemotherapy in Neoadjuvant Treatment of Resectable Esophageal CancerStatus: Completed, Estimated PCD: 2022-04-01
Clinical trial
A Prospective, Randomized Controlled Clinical Study of The Efficacy and Safety of Taurine Combined With Serplulimab and Chemotherapy Versus Serplulimab Combined With Chemotherapy for Treatment of Locally Advanced Gastric or Gastroesophageal Junction AdenocarcinomaStatus: Recruiting, Estimated PCD: 2024-12-31
Clinical trial
An Exploratory Clinical Study of Zimberelimab Combined With Albumin-bound Paclitaxel and Cisplatin in Neoadjuvant Treatment of Locally Advanced Cervical CancerStatus: Recruiting, Estimated PCD: 2026-12-30
Clinical trial
A Single-arm Clinical Study to Investigate the Efficacy and Safety of Neoadjuvant PD-1 Inhibitor (Sintilimab), Anlotinib Combined With Chemotherapy in Resectable Stage IIA-IIIB NSCLCStatus: Active (not recruiting), Estimated PCD: 2023-12-30
Clinical trial
Efficacy and Safety of Fingolimod in Minimal Invasive Treatment of Intracerebral HemorrhageStatus: Not yet recruiting, Estimated PCD: 2025-06-30
Clinical trial
Pembrolizumab Plus Albumin Paclitaxel or 5-fluorouracil and Cisplatin Versus 5-fluorouracil and Cisplatin in Neoadjuvant Therapy for Resectable Esophageal Squamous Cell Carcinoma: a Prospective, Randomized Controlled Trial StudyStatus: Recruiting, Estimated PCD: 2031-12-31
Clinical trial
A Multi-center, Randomized, Double-blind, Placebo-controlled Clinical Trial of the Efficacy and Safety of Tocilizumab in the Treatment of Generalized Myasthenia GravisStatus: Recruiting, Estimated PCD: 2024-03-31
Clinical trial
The Treatment Effect of Baricitinib for the Secondary Pulmonary Complications Following Spontaneous Subarachnoid HemorrhageStatus: Not yet recruiting, Estimated PCD: 2026-12-31
Clinical trial
One Arm Exploratory Trial of Efficacy and Safety of TNT Plus Mode With Neoadjuvant Radiotherapy in the Treatment of Locally Advanced Medium-low Rectal CancerStatus: Not yet recruiting, Estimated PCD: 2024-11-10
Clinical trial
Prospective, Single Arm, Single Center Exploratory Study on the New Adjuvant Therapy of Camrelizumab Combined With XELOX Regimen for Locally Advanced Gastric CancerStatus: Recruiting, Estimated PCD: 2024-03-01
Clinical trial
An Explorative Study on Camrelizumab Combined With Albumin-bound Paclitaxel and Platinum in Neoadjuvant Treatment of Resectable Non-small-cell Lung CarcinomaStatus: Active (not recruiting), Estimated PCD: 2023-11-01
Clinical trial
The Therapeutic Effect of Irinotecan Liposomes Combined With Cisplatin/Carboplatin for Platinum Sensitive Recurrent Small Cell Lung CancerStatus: Recruiting, Estimated PCD: 2025-09-15
Clinical trial
Phase II Study of Neoadjuvant Adebrelimab, Docetaxel, Oxaliplatin, and S-1 in Patients With Resectable Advanced Gastric CancerStatus: Recruiting, Estimated PCD: 2025-05-20
Clinical trial
The Prospective Cohort Study of Neoadjuvant Therapy With Sintilimab (PD-1 Inhibitor) Combined With Chemotherapy in Resectable Esophageal Squamous Cell CarcinomaStatus: , Estimated PCD: 2024-06-20
Clinical trial
A Phase II, Prospective, Randomized, Open Label, Multi-center Study of Tislelizumab Combined With Anlotinib and Platinum Doublet Chemotherapy as Neoadjuvant/Adjuvant With Resectable Stage II-IIIB Non-Small Cell Lung CancerStatus: Not yet recruiting, Estimated PCD: 2025-06-10
Clinical trial
Observational Study on the Efficacy and Safety of Adebrelimab Combined With Apatinib in Maintenance Therapy for Extensive-Stage Small Cell Lung CancerStatus: Recruiting, Estimated PCD: 2025-12-20
Clinical trial
A Prospective Cohort Study of Neoadjuvant Chemotherapy Plus Sintillumab in the Treatment of Resectable NSCLCStatus: Not yet recruiting, Estimated PCD: 2025-12-31
Clinical trial
A Multicenter Randomized Controlled Trial of Neoadjuvant Adebrelimab Combined With Chemotherapy for Resectable Small Cell Lung Cancer (SCLC)Status: Recruiting, Estimated PCD: 2025-12-30